Search

Your search keyword '"DePriest, P.D."' showing total 31 results
Start Over Author "DePriest, P.D."
31 results on '"DePriest, P.D."'

1. Management of adnexal masses in postmenopausal women

Author

Van Nagell, J.R. and Depriest, P.D.

Subjects
Postmenopausal women, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajog.2005.04.051 Byline: J.R. van Nagell, P.D. DePriest Author Affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Markey Cancer Center, University of Kentucky Chandler Medical Center, Lexington, KY Article History: Received 5 April 2005

Published
2005

3. Preoperative radiation therapy followed by extrafascial hysterectomy in patients with Stage II endometrial carcinoma

Author

Higging, R.V., van Nagell, J.R., Jr., Horn, E.J., Roberts, S.L., Donaldson, E.S., Gallion, H.H., DePriest, P.D., Powell, D.E., and Kryscio, R.J.

Subjects
Endometrial cancer -- Care and treatment, Radiotherapy -- Evaluation, Hysterectomy -- Evaluation, Health
Abstract

In 1989, the International Federation of Gynecology and Obstetrics (FIGO), changed their system for defining the stages of endometrial cancer. In the new system, the stage is determined by surgical findings. While this new system may provide better data, implicit in the staging system is that surgery is the first step of treatment. The authors recount their success using radiation therapy prior to surgery in the treatment of Stage II endometrial cancer. In Stage II endometrial cancer, the uterine cervix is involved. The five-year survival rate for Stage II disease is thought to range from 60 to 70 percent, in contrast with the 85 percent survival found among Stage I patients. Over a 22-year-period, the authors treated 74 patients with Stage II endometrial carcinoma. The patients were given external beam irradiation followed by the implantation of a radioactive capsule. Surgery was performed no sooner than four weeks after the completion of radiation therapy. The uterus and cervix were removed, as were the ovaries and adjacent tissues. The lymph nodes were dissected to determine if the spread of cancer had begun. Over follow-up periods, which averaged 5.4 years, 11 patients developed recurrent cancer. The five-year disease-free survival rate was 88 percent and the 10-year disease-free survival rate was 76 percent. These results indicate great success using preoperative radiation in the treatment of Stage II endometrial cancer. The new FIGO staging system might incline physicians to administer radiotherapy after surgery. This inclination should be resisted until it can be reliably shown that the excellent results of preoperative radiotherapy can be preserved. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

4. Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography

Author

Van Nagell, J.R., Jr., DePriest, P.D., Puls, L.E., Donaldson, E.S., Gallion, H.H., Pavlik, E.J., Powell, D.E., and Kryscio, R.J.

Subjects
Ultrasound imaging -- Evaluation, Medical screening -- Evaluation, Ovarian cancer -- Diagnosis, Adenocarcinoma -- Diagnosis, Postmenopausal women -- Health aspects, Health
Abstract

It is estimated that 20,700 cases of ovarian cancer will be diagnosed in the US this year, and that 12,500 women will die of this disease. The cure rate for Stage I ovarian cancer may be as high as 90 percent, but because the disease causes no symptoms in its early stages, the majority of cases are diagnosed late. In more advanced stages, five-year survival rates fall to 15 or 20 percent. It is estimated that if the fraction of cases diagnosed in early stages could be increased to 80 percent the mortality rate could be cut in half. One method for improving the diagnosis of early stage ovarian cancer is by screening using transvaginal ultrasonography. With this method, a ultrasonic sound generator is inserted into the vagina to obtain a clearer image than can be obtained from the body's surface. The ultrasound image is then used to calculate the volume of the ovaries. An abnormally large volume or an unusual echo is indication for further tests. The efficacy of this method for early screening was evaluated in 1,300 postmenopausal women without any history of pelvic tumors. Transvaginal ultrasonography revealed ovarian abnormalities in 33 patients; 27 of these patients underwent exploratory laparotomy, the opening of the abdomen for direct examination of the tissues. All 27 patients had some sort of ovarian tumor. The most common finding was the serous cystadenoma, a benign tumor, which was observed in 14 cases. However, malignant adenocarcinoma of the ovary was found in two patients. In both cases, the Stage I cancer was undetectable by physical examination or by blood tests for tumor markers. Both patients were successfully treated and are alive and well. During follow-up, none of the other patients had negative findings on the imaging screening test developed ovarian cancer. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

6. Primary appendiceal cancer: Gynecologic manifestations and treatment options

Author

Dietrich, C.S., primary, DeSimone, C.P., additional, Modesitt, S.C., additional, DePriest, P.D., additional, Ueland, F.R., additional, Pavlik, E.J., additional, Kryscio, R., additional, Cibull, M., additional, Huh, W., additional, Partridge, E., additional, Numnum, T.M., additional, Schilder, J., additional, Higgins, R.V., additional, and van Nagell, J.R., additional

Published
2007
Full Text
View/download PDF

12. Lymph Node Metastases and Prognosis in Patients with Stage IA2Cervical Cancer

Author

Buckley, S.L., primary, Tritz, D.M., additional, Van Le, L., additional, Higgins, R., additional, Sevin, B.U., additional, Ueland, F.R., additional, DePriest, P.D., additional, Gallion, H.H., additional, Bailey, C.L., additional, Kryscio, R.J., additional, Fowler, W., additional, Averette, H., additional, and van Nagell, Jr., J.R., additional

Published
1996
Full Text
View/download PDF

29. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia

Author

Hunter, J.E., Tritz, D.E., Howell, M.G., DePriest, P.D., Gallion, H.H., Andrews, S.J., Kryscio, R.J., and Van Nagell, J.R., Jr.

Subjects
Endometrial cancer -- Risk factors, Hyperplasia -- Prognosis, Cancer -- Cytopathology, Business, Health care industry
Abstract

AUTHORS: J.E. Hunter, D.E. Tritz, M.G. Howell, P.D. DePriest, H.H. Gallion, S.J. Andrews, R.J. Kryscio and J.R. Van Nagell Jr. University of Kentucky Medical Center, Lexington, Kentucky. According to an [...]

Published
1994

31. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)

Author

Dietrich, C.S., Modesitt, S.C., DePriest, P.D., Ueland, F.R., Wilder, J., Reedy, M.B., Pavlik, E.J., Kryscio, R., Cibull, M., Giesler, J., Manahan, K., Huh, W., Cohn, D., Powell, M., Slomovitz, B., Higgins, R.V., Merritt, W., Hunter, J., Puls, L., and Gehrig, P.

Subjects
*CANCER patients, *IMMUNOLOGICAL adjuvants, *ANTINEOPLASTIC agents, *DRUG therapy
Abstract

Abstract: Objective. : To determine the efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Methods. : A retrospective multi-institutional investigation was performed to identify surgically staged patients with Stage I UPSC who were (1) treated after surgery with 3–6 courses of platinum-based chemotherapy without radiation from 1990–2003, and (2) followed for a minimum of 12 months, or until recurrence. Results. : Six patients (IA—2, IB—3, IC—1) were treated with carboplatin (AUC 6) or cisplatin (50 mg/m2) alone. One patient recurred to the vagina, was treated with chemo-radiation, and is alive and well at 122 months. One patient recurred to the lung, liver, and brain, and died of disease at 24 months. The remaining 4 patients are alive with no evidence of disease 15–124 months (mean 62 months) after treatment. Two patients (IB-1, IC-1) were treated with cisplatin (50 mg/m2) and cyclophosphamide (1000 mg/m2), and both are alive and well with no evidence of disease 75 and 168 months after treatment. Twenty-one patients (IA—5, IB—13, IC—3) were treated with a combination of carboplatin (AUC 6) and paclitaxel (135 mg/m2–175 mg/m2). One patient recurred to the vagina after 3 cycles of carboplatin/paclitaxel, and was treated with chemo-radiation. She is now without evidence of disease 10 months after treatment. At present, all 21 patients with Stage I UPSC treated following surgical staging with carboplatin/paclitaxel chemotherapy are alive and well with no evidence of disease 10–138 months (mean 41 months) after treatment. Conclusion. : Combination carboplatin/paclitaxel chemotherapy following surgery is effective in the treatment of Stage I UPSC. [Copyright &y& Elsevier]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results